CN119462802A - 抗病毒前体药物及其药物组合物 - Google Patents

抗病毒前体药物及其药物组合物 Download PDF

Info

Publication number
CN119462802A
CN119462802A CN202411383875.4A CN202411383875A CN119462802A CN 119462802 A CN119462802 A CN 119462802A CN 202411383875 A CN202411383875 A CN 202411383875A CN 119462802 A CN119462802 A CN 119462802A
Authority
CN
China
Prior art keywords
compound
suspension
fluoro
purin
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411383875.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·K·查特吉
A·K·古普塔
A·M·埃利亚森
S·B·约瑟夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN119462802A publication Critical patent/CN119462802A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN202411383875.4A 2019-09-11 2020-09-11 抗病毒前体药物及其药物组合物 Pending CN119462802A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962898679P 2019-09-11 2019-09-11
US62/898,679 2019-09-11
PCT/US2020/050511 WO2021050956A1 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof
CN202080077922.6A CN114793421B (zh) 2019-09-11 2020-09-11 抗病毒前体药物及其药物组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080077922.6A Division CN114793421B (zh) 2019-09-11 2020-09-11 抗病毒前体药物及其药物组合物

Publications (1)

Publication Number Publication Date
CN119462802A true CN119462802A (zh) 2025-02-18

Family

ID=74866690

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202411383875.4A Pending CN119462802A (zh) 2019-09-11 2020-09-11 抗病毒前体药物及其药物组合物
CN202080075497.7A Active CN114929236B (zh) 2019-09-11 2020-09-11 抗病毒前药及其制剂
CN202080077922.6A Active CN114793421B (zh) 2019-09-11 2020-09-11 抗病毒前体药物及其药物组合物
CN202410626114.0A Pending CN118580291A (zh) 2019-09-11 2020-09-11 抗病毒前药及其制剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202080075497.7A Active CN114929236B (zh) 2019-09-11 2020-09-11 抗病毒前药及其制剂
CN202080077922.6A Active CN114793421B (zh) 2019-09-11 2020-09-11 抗病毒前体药物及其药物组合物
CN202410626114.0A Pending CN118580291A (zh) 2019-09-11 2020-09-11 抗病毒前药及其制剂

Country Status (18)

Country Link
US (3) US20220323476A1 (cg-RX-API-DMAC7.html)
EP (2) EP4028019A4 (cg-RX-API-DMAC7.html)
JP (4) JP7703518B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220066303A (cg-RX-API-DMAC7.html)
CN (4) CN119462802A (cg-RX-API-DMAC7.html)
AU (4) AU2020346907B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022004424A2 (cg-RX-API-DMAC7.html)
CA (2) CA3150467A1 (cg-RX-API-DMAC7.html)
CL (4) CL2022000587A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022005128A2 (cg-RX-API-DMAC7.html)
CR (3) CR20260001A (cg-RX-API-DMAC7.html)
DO (2) DOP2022000055A (cg-RX-API-DMAC7.html)
IL (5) IL319709A (cg-RX-API-DMAC7.html)
MX (4) MX2022002897A (cg-RX-API-DMAC7.html)
PE (2) PE20221037A1 (cg-RX-API-DMAC7.html)
PH (2) PH12022550528A1 (cg-RX-API-DMAC7.html)
UA (1) UA130229C2 (cg-RX-API-DMAC7.html)
WO (2) WO2021050956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
MX2022002897A (es) * 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
KR102987126B1 (ko) * 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
EP4157272B1 (en) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
US20240190878A1 (en) * 2021-03-16 2024-06-13 The Scripps Research Institute Antiviral prodrugs of etv and formulations thereof
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN121358747A (zh) 2023-06-27 2026-01-16 吉利德科学公司 核苷逆转录酶易位抑制剂的固体形式
TW202500140A (zh) * 2023-06-27 2025-01-01 美商基利科學股份有限公司 製備抗病毒前藥之方法及中間物
FI132042B1 (en) 2024-01-17 2026-05-04 Metso Finland Oy Precipitation of calcium compounds in liquid extraction systems

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283067A (en) 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
US5192749A (en) 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
FR2694693B1 (fr) 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
DE60005502T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-purin-nukleoside
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
EA200800932A1 (ru) 2005-09-26 2008-10-30 Фармассет, Инк. Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
US20130244966A1 (en) 2011-12-12 2013-09-19 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
JP6768796B2 (ja) 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
WO2017100108A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
FR3053281B1 (fr) 2016-06-30 2020-03-27 Banque De France Procede de fabrication d'un document de securite presentant un signe de securite a contraste de brillance
US10185393B2 (en) 2017-04-03 2019-01-22 Facebook Technologies, Llc Waveguide display with spatially switchable grating
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
MA53280A (fr) 2018-08-09 2021-11-17 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US11572595B2 (en) * 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
CN121358747A (zh) 2023-06-27 2026-01-16 吉利德科学公司 核苷逆转录酶易位抑制剂的固体形式
TW202500140A (zh) 2023-06-27 2025-01-01 美商基利科學股份有限公司 製備抗病毒前藥之方法及中間物

Also Published As

Publication number Publication date
JP2025137788A (ja) 2025-09-19
IL320979A (en) 2025-07-01
IL290861A (en) 2022-04-01
JP7719769B2 (ja) 2025-08-06
EP4028020A1 (en) 2022-07-20
CA3150467A1 (en) 2021-03-18
CR20220110A (es) 2022-06-16
MX2022002897A (es) 2022-05-16
PE20221036A1 (es) 2022-06-17
NZ786022A (en) 2025-05-30
MX2025011432A (es) 2025-11-03
CN118580291A (zh) 2024-09-03
BR112022004424A2 (pt) 2022-05-31
EP4028019A1 (en) 2022-07-20
AU2020346908B2 (en) 2026-02-12
NZ786018A (en) 2025-05-30
WO2021050956A1 (en) 2021-03-18
CR20220109A (es) 2022-06-07
US20220332751A1 (en) 2022-10-20
CL2022000601A1 (es) 2022-10-28
IL320979B1 (en) 2026-04-01
IL290919B2 (en) 2025-10-01
PH12022550527A1 (en) 2023-09-04
MX2025014404A (es) 2026-01-07
US12569510B2 (en) 2026-03-10
CA3150418A1 (en) 2021-03-18
PH12022550528A1 (en) 2023-09-04
PE20221037A1 (es) 2022-06-17
IL290919B1 (en) 2025-06-01
US20220323476A1 (en) 2022-10-13
KR20220066303A (ko) 2022-05-24
CO2022005128A2 (es) 2022-05-10
IL290919A (en) 2022-04-01
CN114929236B (zh) 2024-06-07
EP4028020A4 (en) 2023-09-27
IL290861B1 (en) 2025-04-01
WO2021050961A1 (en) 2021-03-18
MX2022002899A (es) 2022-05-16
AU2020346907A1 (en) 2022-03-24
AU2026204849A1 (en) 2026-07-09
IL327111A (en) 2026-05-01
CN114793421B (zh) 2024-09-13
CL2022000587A1 (es) 2022-10-28
DOP2022000055A (es) 2022-06-15
IL319709A (en) 2025-05-01
AU2020346907A2 (en) 2022-06-16
CN114929236A (zh) 2022-08-19
JP2025096427A (ja) 2025-06-26
EP4028019A4 (en) 2024-04-17
CN114793421A (zh) 2022-07-26
AU2026203582A1 (en) 2026-05-28
CR20260001A (es) 2026-04-12
CO2022004681A2 (es) 2022-07-19
DOP2022000056A (es) 2022-06-15
KR20220066302A (ko) 2022-05-24
IL290861B2 (en) 2025-08-01
IL320979B2 (en) 2026-08-01
UA130229C2 (uk) 2025-12-24
BR112022004417A2 (pt) 2022-06-21
AU2020346908A2 (en) 2022-06-16
CL2024003241A1 (es) 2025-01-03
AU2020346908A1 (en) 2022-03-24
JP2022547978A (ja) 2022-11-16
AU2020346907B2 (en) 2026-07-16
JP7703518B2 (ja) 2025-07-07
CL2025003801A1 (es) 2026-03-27
JP2022547558A (ja) 2022-11-14
US20230390318A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
CN114793421B (zh) 抗病毒前体药物及其药物组合物
US7947670B2 (en) Ansamycin formulations and methods of use thereof
JP2022517115A (ja) ベンゾアゼピン化合物含有凍結乾燥組成物
US20120135965A1 (en) Amorphous fosamprenavir calcium
AU739673B2 (en) Lyophilized compositions containing sphingoglycolipid and process for preparing them
US8349811B2 (en) Stable 6-methoxy-2′,3′-dideoxyguanosine, method for preparing the same and pharmaceutical composition containing the same
AU628137B2 (en) Pharmaceutical treatment
CN112898346B (zh) 水溶性多环化合物及其药物组合物和用途
KR102788736B1 (ko) 16α-브로모-3β-히드록시-5α-안드로스탄-17-케톤 및 이의 수화물, 유도체 및 유사체를 포함하는 수성 현탁액 조성물, 제제 및 수분산 건조 조성물
HK40076147A (en) Antiviral prodrugs and pharmaceutical compositions thereof
HK40123101A (en) Antiviral prodrugs and pharmaceutical compositions thereof
EA049868B1 (ru) Противовирусные пролекарства и их фармацевтические композиции
HK40076147B (en) Antiviral prodrugs and pharmaceutical compositions thereof
JPH0643437B2 (ja) レベカマイシン類似体の安定な溶液およびその製造
US20160095925A1 (en) Stable formulation of azacitidine or salts thereof and their process for preparation
HU199289B (en) Process for production of liofilized medical compositions containing derivatives of phenil-quinoline-carbonic acid
EA053005B1 (ru) Противовирусные пролекарства и их фармацевтические композиции
CN108948084B (zh) 替诺福韦双-l-氨基酸酯及其制备方法
CN117750940A (zh) 尿苷三乙酸酯无定形制剂
EP2303228B1 (en) Fosphenytoin composition
US20240180903A1 (en) Injectable pharmaceutical composition, preparation method therefor and use thereof
RU2255086C1 (ru) 1-метил-2-фенилтиометил-3-карбэтокси-4-диметиламинометил-5-окси-6- броминдола мезилат, обладающий противовирусной активностью, и фармацевтическая композиция с его использованием
EA050325B1 (ru) Противовирусные пролекарства и их композиции
EA045403B1 (ru) Лиофилизированная композиция, содержащая соединение бензоазепина
HK40060651A (en) Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40123101

Country of ref document: HK